Search

[Purpose/Significance] Mobile short video apps like Tiktok have become one of the most frequently used tools to obtain/exchange health information in post-epidemic era. This study analyzed the complex relationships between the antecedents and users' health information adoption in mobile short video apps in terms of necessary and sufficient conditions, in order to optimize users' experience with health information adoption systematically, which in turn generates users' sustainability. [Method/Process] Based on both the information adoption model (IAM) and the heuristic-systematic model (HSM), this study constructed a health information adoption model of mobile short videos, in which five predictor variables (content quality, expression quality, information source credibility, app's reputation, perceived information usefulness) and an outcome variable (health information adoption) were included. The construct validity, reliability and symmetrical relationships between the five predictor variables and an outcome condition were examined using structural equation model (SEM) method. Fuzzy-set qualitative comparative analysis (fsQCA) was used to examine and reveal the configuration models. [Results/Conclusions] The results from PLS-SEM method and fsQCA validated the IAM and HSM in the context of mobile short video apps. Specifically, the results from PLS-SEM show that systematic and heuristic clues jointly affect users' adoption of health information. Content quality, app's reputation and information resource credibility significantly impact perceived information usefulness, and further affect the health information adoption. Expression quality has a significant effect on content quality, but no obvious effects on perceived information usefulness and health information adoption. The results of fsQCA reveal three configurations to affect users' health information adoption (i.e., content quality * expression quality * perceived information usefulness * information resource credibility), and another three configurations to affect users' non-adoption i.e., ~content quality * ~perceived information usefulness * ~information resource credibility), in which the latter configurations are asymmetric with the former. The configurations where systematic clues are predominant (S1a and S1b) are more sufficient for promoting users' health information adoption. N1(~ content quality * ~ perceived information usefulness * ~ information resource credibility). This shows the most sufficient configuration path in non-adoption. This study is aimed at exploring users' adoption and non-adoption decision-making process in a growing context of mobile short video apps like Tiktok, in order to contribute to helpful advice for the better management of these apps, which will eventually optimize users' experience with health information behavior. Users always engaged in many kinds of information activities such as information sharing, retweeting, adoption, and some relationships between these activities may exists. Due to the limited length, we did not consider users' other information behavior i.e., retweeting) and the relationship between them in this context, which could possibly be further research directions.

TP53 mutation is one of the most common genetic alterations in urothelial carcinoma (UrCa), and heterogeneity of TP53 mutants leads to heterogeneous clinical outcomes. This study aimed to investigate the clinical relevance of specific TP53 mutations in UrCa. In this study, a total of eight cohorts were enrolled, along with matched clinical annotation. TP53 mutations were classified as disruptive and nondisruptive according to the degree of disturbance of p53 protein function and structure. We evaluated the clinical significance of TP53 mutations in our local datasets and publicly available datasets. The co‐occurring events of TP53 mutations in UrCa, along with their therapeutic indications, functional effects, and the tumor immune microenvironment, were also investigated. TP53 mutations were identified in 49.7% of the UrCa patients. Within this group, 25.1% of patients carried TP53Disruptive mutations, a genetic alteration correlated with a significantly poorer overall survival (OS) when compared to individuals with TP53Nondisruptive mutations and those with wild‐type TP53. Significantly, patients with TP53Disruptive mutations exhibit an increased probability of responding favorably to PD‐1/PD‐L1 blockade and chemoimmunotherapy. Meanwhile, there was no noteworthy distinction in OS among patients with varying TP53 mutation status who underwent chemotherapy. Samples with TP53Disruptive mutations showed an enriched APOBEC‐ and POLE‐related mutational signature, as well as an elevated tumor mutation burden. The sensitivity to immunotherapy in tumors carrying TP53Disruptive mutation may be attributed to the inflamed tumor microenvironment characterized by increased CD8+T cell infiltration and interferon‐gamma signaling activation. In conclusion, UrCa patients with TP53Disruptive mutations have shown reduced survival rates, yet they may respond well to PD‐1/PD‐L1 blockade therapy and chemoimmunotherapy. By distinguishing specific TP53 mutations, we can improve risk stratification and offer personalized genomics‐guided therapy to UrCa patients. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. [ABSTRACT FROM AUTHOR]

Background: Luminal and Basal are the primary intrinsic subtypes of muscle-invasive bladder cancer (MIBC). The presence of CD8+ T cells infiltration holds significant immunological relevance, potentially influencing the efficacy of antitumor responses. This study aims to synergize the influence of molecular subtypes and CD8+ T cells infiltration in MIBC. Methods: This study included 889 patients with MIBC from Zhongshan Hospital, The Cancer Genome Atlas, IMvigor210 and NCT03179943 cohorts. We classified the patients into four distinct groups, based on the interplay of molecular subtypes and CD8+ T cells and probed into the clinical implications of these subgroups in MIBC. Results: Among patients with Luminal-CD8+Thigh tumors, the confluence of elevated tumor mutational burden and PD-L1 expression correlated with a heightened potential for positive responses to immunotherapy. In contrast, patients featured by Luminal-CD8+Tlow displayed a proclivity for deriving clinical advantages from innovative targeted interventions. The Basal-CD8+Tlow subgroup exhibited the least favorable three-year overall survival outcome, whereas their Basal-CD8+Thigh counterparts exhibited a heightened responsiveness to chemotherapy. Conclusions: We emphasized the significant role of immune-molecular subtypes in shaping therapeutic approaches for MIBC. This insight establishes a foundation to refine the process of selecting subtype-specific treatments, thereby advancing personalized interventions for patients. [ABSTRACT FROM AUTHOR]

Muscle‐invasive bladder cancer (MIBC) is a disease characterized by molecular and clinical heterogeneity, posing challenges in selecting the most appropriate treatment in clinical settings. Considering the significant role of CD4+ T cells, there is an emerging need to integrate CD4+ T cells with molecular subtypes to refine classification. We conducted a comprehensive study involving 895 MIBC patients from four independent cohorts. The Zhongshan Hospital (ZSHS) and The Cancer Genome Atlas (TCGA) cohorts were included to investigate chemotherapeutic response. The IMvigor210 cohort was included to assess the immunotherapeutic response. NCT03179943 was used to evaluate the clinical response to a combination of immune checkpoint blockade (ICB) and chemotherapy. Additionally, we evaluated genomic characteristics and the immune microenvironment to gain deeper insights into the distinctive features of each subtype. We unveiled four immune‐molecular subtypes, each exhibiting distinct clinical outcomes and molecular characteristics. These subtypes include luminal CD4+ Thigh, which demonstrated benefits from both immunotherapy and chemotherapy; luminal CD4+ Tlow, characterized by the highest level of fibroblast growth factor receptor 3 (FGFR3) mutation, thus indicating potential responsiveness to FGFR inhibitors; basal CD4+ Thigh, which could benefit from a combination of ICB and chemotherapy; and basal CD4+ Tlow, characterized by an immune suppression microenvironment and likely to benefit from transforming growth factor‐β (TGF‐β) inhibition. This immune‐molecular classification offers new possibilities for optimizing therapeutic interventions in MIBC. [ABSTRACT FROM AUTHOR]